GENEDRIVE PLC — Regulatory Filings 2018

May 17, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4693O

Genedrive PLC

17 May 2018

For release: 17 May 2018

Circular re Proposed Disposal

Genedrive plc ("the Company")

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, confirms that the circular to shareholders convening a General Meeting for 4 June 2018 in connection with the proposed disposal of the Company's contract research and pharmacogenomics divisions has been posted to shareholders.

Copies of the circular may also be found on the Company's website (www.genedriveplc.com) 

- Ends -

For further details please contact:

genedrive plc	+44 (0)161 989 0245
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP
James Steel	+44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications	+44 (0)203 709 5700
Chris Gardner
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF assay has been launched in India and a Genedrive® HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions.

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

CIRFKODNNBKDKPD